Evidence map›Paper›PMID 32056660›Full record

ArticleBiosensors & bioelectronics2020

Smartphone based on-chip fluorescence imaging and capillary flow velocity measurement for detecting ROR1+ cancer cells from buffy coat blood samples on dual-layer paper microfluidic chip.

Tiffany-Heather Ulep, Ryan Zenhausern, Alana Gonzales, David S Knoff, Paula A Lengerke Diaz, Januario E Castro, Jeong-Yeol Yoon

Open access · greenAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tiffany-Heather UlepDepartment of Biomedical Engineering, The University of Arizona, Tucson, AZ, 85721, United States.
Ryan ZenhausernDepartment of Biomedical Engineering, The University of Arizona, Tucson, AZ, 85721, United States.
Alana GonzalesDepartment of Biomedical Engineering, The University of Arizona, Tucson, AZ, 85721, United States.
David S KnoffDepartment of Biomedical Engineering, The University of Arizona, Tucson, AZ, 85721, United States.
Paula A Lengerke DiazHematology Oncology Division, Mayo Clinic, Phoenix, AZ, 85054, United States.
Januario E CastroHematology Oncology Division, Mayo Clinic, Phoenix, AZ, 85054, United States.
Jeong-Yeol YoonDepartment of Biomedical Engineering, The University of Arizona, Tucson, AZ, 85721, United States. Electronic address: jyyoon@email.arizona.edu.
University of Arizona · USWinnMed · US

Funding

MARC/Biomedical Research and Training Program at the University of ArizonaT34GM008718 · NIGMS · UNIVERSITY OF ARIZONA · PI MIRANDA, KATRINA M. · 1999 to 2021
$8.6M
Cardiovascular Biomedical Engineering Training GrantT32HL007955 · NHLBI · UNIVERSITY OF ARIZONA · PI BARTON, JENNIFER KEHLET · 2001 to 2020
$5.1M
NHLBI NIH HHS T32 HL007955NIGMS NIH HHS T34 GM008718
6 · The paper itself

Abstract

Diagnosis of hematological cancer requires complete white blood cell count, followed by flow cytometry with multiple markers, and cytology. It requires substantial time and specialized training. A dual-layer paper microfluidic chip was developed as a quicker, low-cost, and field-deployable alternative to detect ROR1+ (receptor tyrosine-like orphan receptor one) cancer cells from the undiluted and untreated buffy coat blood samples. The first capture layer consisted of a GF/D glass fiber substrate, preloaded with cancer specific anti-ROR1 conjugated fluorescent particles to its center for cancer cell capture and direct smartphone fluorescence imaging. The second flow layer was comprised of a grade 1 cellulose chromatography paper with wax-printed four channels for wicking and capillary flow-based detection. The flow velocity was used as measure of antigen concentration in the buffy coat sample. In this manner, intact cells and their antigens were separated and independently analyzed by both imaging and flow velocity analyses. A custom-made smartphone-based fluorescence microscope and automated image processing and particle counter software were developed to enumerate particles on paper, with the limit of detection of 1 cell/μL. Flow velocity analysis showed even greater sensitivity, with the limit of detection of 0.1 cells/μL in the first 6 s of assay. Comparison with capillary flow model revealed great alignment with experimental data and greater correlation to viscosity than interfacial tension. Our proposed device is able to capture and on-chip image ROR1+ cancer cells within a complex sample matrix (buffy coat) while simultaneously quantifying cell concentration in a point-of-care manner.

Indexed as

Biosensing TechniquesBiomarkers, TumorBlood Buffy CoatHumansLeukemia, Lymphocytic, Chronic, B-CellMicrofluidicsOptical ImagingReceptor Tyrosine Kinase-like Orphan ReceptorsSmartphoneBiomarkers, TumorReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanAntibody receptor tyrosine kinase-like orphan receptor 1 (ROR1)Capillary actionChronic lymphocytic leukemia (CLL)ImmunoagglutinationParticle aggregation

Identifiers

PMID32056660
PMCPMC7047888
OpenAlexW3000854404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.